Diffuse large B-cell lymphoma: Current strategies and future directions

Cancer Control

Volumn 19, Issue 3, 2012, Pages 204-213

  Cultrera, Jennifer L ^a   Dalia, Samir M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; BLINATUMOMAB; BORTEZOMIB; CARBOPLATIN; CD20 ANTIBODY; CD4 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; INOTUZUMAB OZOGAMICIN; IPILIMUMAB; LENALIDOMIDE; METHOTREXATE; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE; VINDESINE;

ARTICLE; ASTHENIA; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBELLUM DISEASE; COUGHING; DRUG APPROVAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; SPEECH DISORDER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84864517049     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900305     Document Type: Article

References (49)

1. NCCN Guidelines for Treatment of Non-Hodgkin Lymphoma. http:// http://www.nccn.org. Accessed May 30, 2012.
2. ®-sap. ASH Self-Assessment Program. 4th ed. 2010:511-554.
3. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008.
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
6. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
7. Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating fi ndings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17(19):6112-6117.
8. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profi ling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
9. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential effi cacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
11. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifi es diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-502.
12. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339(1):21-26.
13. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients. J Clin Oncol. 2007;25:787-792
14. Gaynor ER, Unger JM, Miller TP, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol. 2001;19(3):750-755.
15. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-1006.
16. Ujjani C, Cheson BD. Monoclonal antibodies in advanced B-cell lymphomas. Oncology (Williston Park). 2010;24(2):156-166.
17. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022.
18. Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, fi rst randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3741.
19. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(15S May 20 suppl):8509. Abstract.
20. Philip T, Chauvin F, Armitage, J, et al. Parma international protocol: pilot study of DHAP followed by involved-fi eld radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77(7):1587-1592.
21. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-1545.
22. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and effi cacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-100.
23. Cartron G, Thieblemont C, Solal-Celigny P, et al. Promising effi cacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients-fi rst results from a phase II study in patients with relapsed/refractory DLBCL and MCL. Blood (ASH Annual Meeting Abstracts). 2010; 116(21):2878.
24. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20):3346-3353.
25. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.
26. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(26):4371-4377.
27. Forero-Torres A, Bartlett NL, Nasta SD, et al. A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed diffuse large b-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114:586.
28. Ansell S. A phase 2b trial comparing dacetuzumab + R-ICE vs placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma. Presented at the 11th International Conference on Malignant Lymphoma, June 18, 2011. Abstract 140.
29. ®antibody blinatumomab. Blood (ASH Annual Meeting Abstracts). 2009;114:2723.
30. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
31. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 15:6446-6453.
32. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044-3051.
33. Rotem-Yehudar R, Armand P, Devine S, et al. 1216 the humanized anti PD-1 antibody, CT-011, increases specifi c CD4+ effector/memory and memory T lymphocytes in patients with diffuse large B cell lymphoma (DLBCL) following autologous stem cell transplantation (AuSCT). Blood (ASH Annual Meeting Abstracts). 2009;114:1216.
34. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093.
35. Dang NH, Smith MR, Offner F, et al. Anti-CD22 Immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114:584.
36. Wagner-Johnston N, Goy A, Feldman T, et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab in relapsed DLBCL patients followed by stem cell transplantation: preliminary safety and effi cacy. Blood (ASH Annual Meeting Abstracts). 2010;116:2883.
37. Lenalidomide investigators brochure. http://www.celgene.com/. Accessed May 31, 2012.
38. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-1627.
39. Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park). 2009;23(7):610-615.
40. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058-5066.
41. PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identifi cation. J Clin Oncol. 2011;29(suppl):TPS226.
42. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230-2237.
43. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has signifi cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
44. Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21(3):355-361.
45. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
46. Byrd JC, Blum KA, Burger JA, et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. J Clin Oncol. 2011;29(suppl):6508.
47. Advani R, Sharman JP, Smith SM, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol. 2010; 28:15(suppl):8012.
48. Staudt LM, Dunleavy K, Buggy JJ, et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL Blood (ASH Annual Meeting Abstracts). 2011;118:2716.
49. Evans E, Tester R, Aslanian S, et al. Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. Blood (ASH Annual Meeting Abstracts). 2011;118:3485.